Skip to main content

Table 3 Most frequent on-treatment adverse events (≥3% any treatment group) intent-to-treat population

From: Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial

n (%) FF 100mcg (n = 51) FF/VI 100/25mcg (n = 51) Placebo (n = 51)
Headache 11 (22) 5 (10) 9 (18)
Oropharyngeal pain 2 (4) 2 (4) 2 (4)
Nasopharyngitis 2 (4) 0 3 (6)
Cough 3 (6) 0 1 (2)
Chest discomfort 0 0 3 (6)
Mouth ulceration 2 (4) 2 (4) 0
Nausea 2 (4) 0 2 (4)
Dysphonia 2 (4) 2 (4) 0
Hot flush 0 2 (4) 0
Seasonal allergy a 2 (4) 0 0
  1. aOne subject (2%) had seasonal allergy, reported as allergic rhinitis, during each treatment period.
  2. FF = fluticasone furoate; VI = vilanterol.